Table 2 Lifetime costs and effects of HPV vaccination in Burkina Faso (2022–2031) assuming cross-protection
From: Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study
No vaccine | CECOLIN | GARDASIL-4 | CERVARIX | GARDASIL-9 | |
|---|---|---|---|---|---|
Lifetime costs and effects | |||||
Cervical cancer cases (local) | 25,684 | 13,342 | 13,438 | 8,698 | 7,308 |
Cervical cancer cases (regional) | 14,517 | 7,541 | 7,595 | 4,916 | 4,130 |
Cervical cancer cases (distant) | 21,776 | 11,312 | 11,393 | 7,374 | 6,196 |
Cervical cancer cases with treatment | 61,976 | 32,195 | 32,427 | 20,989 | 17,634 |
Cervical cancer deaths | 51,515 | 26,761 | 26,954 | 17,447 | 14,658 |
DALYs (discounted*) | 221,841 | 115,589 | 116,416 | 75,609 | 63,640 |
Vaccine program costs (discounted*) | US$ 0 | US$ 24,501,708 | US$ 34,663,269 | US$ 36,953,148 | US$ 164,858,263 |
Societal healthcare costs (discounted*) | US$ 12,044,932 | US$ 6,276,740 | US$ 6,321,636 | US$ 4,106,332 | US$ 3,456,536 |
Differences (comparator = no vaccine) | |||||
Cervical cancer cases (local) | - | 12,342 | 12,246 | 16,986 | 18,376 |
Cervical cancer cases (regional) | - | 6,976 | 6,922 | 9,601 | 10,387 |
Cervical cancer cases (distant) | - | 10,464 | 10,383 | 14,402 | 15,580 |
Cervical cancer cases with treatment | - | 29,781 | 29,549 | 40,987 | 44,342 |
Cervical cancer deaths | - | 24,754 | 24,561 | 34,068 | 36,857 |
DALYs (discounted*) | - | 106,252 | 105,425 | 146,232 | 158,201 |
Vaccine program costs (discounted*) | - | US$ 24,501,708 | US$ 34,663,269 | US$ 36,953,148 | US$ 164,858,263 |
Societal healthcare costs (discounted*) | - | -US$ 5,768,192 | -US$ 5,723,296 | -US$ 7,938,600 | -US$ 8,588,396 |
Cost (US$) per DALY averted (comparator = no vaccine) | |||||
Societal cost perspective | - | ||||
Cost (discounted*) | - | US$ 18,733,516 | US$ 28,939,973 | US$ 29,014,548 | US$ 156,269,867 |
DALYs averted (discounted*) | - | 106,252 | 105,425 | 146,232 | 158,201 |
Cost per DALY averted (discounted*) | - | US$ 176 | US$ 275 | US$ 198 | US$ 988 |
Cost (US$) per DALY averted (comparator = next least costly non-dominated** option) | |||||
Societal cost perspective | - | ||||
Cost (discounted*) | - | US$ 18,733,516 | Dominated** | US$ 10,281,032 | US$ 127,255,319 |
DALYs averted (discounted*) | - | 106,252 | Dominated** | 39,980 | 11,969 |
Cost per DALY averted (discounted*) | - | US$ 176 | Dominated** | US$ 257 | US$ 10,632 |